Von Eschenbach Receiving HELP With GOP Nomination Hurdles
Executive Summary
Senate Health, Education, Labor & Pensions committee members are working to end Republican holds on the nomination of FDA Acting Commissioner Andrew von Eschenbach to the permanent post
You may also be interested in...
Von Eschenbach still in limbo
Senate Finance Committee Chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach to be permanent FDA commissioner Nov. 16. The senator objects to von Eschenbach's "failure to comply with the committee's subpoenas over the past six months." In May, Grassley requested a briefing by senior FDA staff, a meeting with a line investigator and access to study data related to Sanofi-Aventis' Ketek (telithromycin) after allegations of data integrity problems in the antibiotic's NDA. Grassley is the third Senator to place a hold on the nomination, following Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.). Senate Health Committee Chair Mike Enzi (R-Wyo.) has vowed to work to lift the holds to allow for confirmation before Congress adjourns (1"The Pink Sheet" Sept. 25, 2006, p. 4)...
Von Eschenbach still in limbo
Senate Finance Committee Chair Chuck Grassley (R-Iowa) places a hold on the nomination of Andrew von Eschenbach to be permanent FDA commissioner Nov. 16. The senator objects to von Eschenbach's "failure to comply with the committee's subpoenas over the past six months." In May, Grassley requested a briefing by senior FDA staff, a meeting with a line investigator and access to study data related to Sanofi-Aventis' Ketek (telithromycin) after allegations of data integrity problems in the antibiotic's NDA. Grassley is the third Senator to place a hold on the nomination, following Sens. David Vitter (R-La.) and Jim DeMint (R-S.C.). Senate Health Committee Chair Mike Enzi (R-Wyo.) has vowed to work to lift the holds to allow for confirmation before Congress adjourns (1"The Pink Sheet" Sept. 25, 2006, p. 4)...
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act